Activity Overview
PD-L1 status and antibody-drug conjugates (ADCs) now anchor frontline treatment selection in metastatic triple-negative breast cancer (mTNBC). Still, community oncologists face variability in PD-L1 assay choice and scoring thresholds, a rapidly expanding ADC evidence base spanning monotherapy and immunotherapy-combination strategies, and toxicity profiles that differ by agent. Applying this evidence in daily practice requires clinicians to interpret biomarker results correctly, weigh trial data against real-world patient factors, and coordinate with multidisciplinary colleagues on testing, treatment selection, and adverse event management.
This online, on-demand webinar brings together renowned experts in mTNBC. In this educational program, these experts discuss recent mTNBC clinical trial data, followed by case presentations and discussions in an interactive format tailored to community oncology practice. The program is designed to translate evolving clinical evidence into practical, real-world decision-making and support personalized care for patients with mTNBC.
This educational activity is an archive of the live presentation held on September 3, 2026.
Target Audience
This educational program is primarily directed toward community-based oncologists, nurses, nurse practitioners/advanced practice providers, and other health care professionals involved in the treatment of TNBC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe how PD-L1 testing impacts treatment planning and regimen selection in patients with newly diagnosed metastatic triple-negative breast cancer (mTNBC)
- Select appropriate frontline strategies for mTNBC based on PD-L1 status, immunotherapy eligibility, patient preferences, and evolving clinical evidence
- Apply practical approaches to toxicity management, patient communication, and workflow integration in community oncology settings
Neil M. Iyengar, MD
Co-Director, Breast Oncology Program
Director, Cancer Survivorship Services
Winship Cancer Institute, Emory University
Atlanta, GA
Disclosures: Consultant/Advisor: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics; Speaker: Cardinal Health, Curio Science, DAVA Oncology, IntrinsiQ Health; Editorial Position: npj Breast Cancer, Oncology; Equity/ Ownership: Bettering Company, Complement Theory; Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat’s Ribbon of Hope, National Cancer Institute/National Institutes of Health; Contracted Research: Novartis, SynDevRx
Girish Kunapareddy, MD
Adjunct Clinical Assistant Professor of Medicine
Indiana University School of Medicine
Medical Director of Oncology Service Line
Union Health
Terre Haute, IN
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Genentech, Novartis, Takeda; Grant/Research Support: Bristol Myers Squibb, Eisai, Geron, GSK, Guardant, Incyte, Natera, Pfizer
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners before the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here